register free | resend password

Sernova Initiates Patient Screening and Recruitment for its US Clinical Trial for Diabetes

ID: 1538133
recent pressrelease next pressrelease

(businesspress24) - Sernova Initiates Patient Screening and Recruitment for its US Clinical Trial for Diabetes

LONDON, ONTARIO -July 5, 2018 - Sernova Corp. (Sernova or the Company) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) announces that patient screening and recruitment has begun in its regenerative medicine US clinical trial for diabetic patients with hypoglycemia unawareness.

Sernovas initial clinical evaluation of the prevascularized Cell Pouch (TM) demonstrated biocompatibility and safety of the Cell Pouch as well as viability and vascularization of its transplanted insulin-producing islets, a first in world achievement in a prevascularized implantable medical device.

This first-in-human work helped frame the design of Sernovas new Phase I/II clinical protocol. Our clinical team at the University of Chicago is excited to initiate this trial of Sernovas transformative technology, said principal investigator, Dr. Piotr Witkowski, M.D., Ph.D.

To support the clinical studys timely execution under the highest quality standards, Sernova and CTI (Clinical Trial and Consulting), a well-respected clinical research organization with deep experience in the regenerative medicine field, are working closely with Dr. Witkowskis team, said Dr. Philip Toleikis, Sernovas President and CEO.

The study is a Phase I/II, non-randomized, open label, single-arm, company sponsored trial. Under the clinical leadership of Dr. Witkowski, University of Chicago Medicine, subjects with hypoglycemia unawareness enrolled in the study under informed consent will be implanted with the Cell Pouch. Following vascularized tissue development in the Cell Pouch, an initial dose of purified islets under strict release criteria will be transplanted into the Cell Pouch.

A sentinel pouch, also transplanted with islets, will be removed for an early assessment of the islet transplant. Subjects will be followed for safety and efficacy measures for approximately six months. At this point a decision will be made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Subjects will then be further followed for one year, with interim participants results released at periodic intervals consistent with an open label study.

About Sernovas Cell Pouch Technologies

The Cell Pouch is a novel, proprietary, scalable, implantable prevascularized macroencapsulation
device for the long-term survival and function of therapeutic cells (donor, stem cell derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device is designed to eliminate concerns of fibrosis upon implantation by incorporating with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin producing cells in humans.

About Diabetes

Type1 Diabetes (T1D) is a life-threatening disease in which the body''s immune system mistakenly attacks and kills the pancreatic cells that produce insulin-a hormone that is essential for life because of its role to help the body use glucose. The existing standard of care for patients with TID is suboptimal. To date, there is no cure for T1D, and people living with the disease are dependent on exogenous insulin therapy to help keep their blood-sugar levels from spiking too high, which can lead to long-term complications such as kidney and heart diseases or an acute, potentially deadly health crisis. Present-day insulin therapy is, however, an imperfect treatment method that requires people with T1D to carefully monitor their blood sugar throughout the day and take multiple, calculated doses of insulin based on food intake, exercise, stress, illness and other factors. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with T1D achieve their long-term blood glucose targets, placing them at risk for T1D-related health complications.

About Sernova Corp

Sernova Corp is developing regenerative medicine therapeutic technologies using an implantable medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit

For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939

Ray Matthews & Associates
Tel: (604) 818-7778

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words expects, plans, anticipates, believes, intends, estimates, projects, potential and similar expressions, or that events or conditions will, would, may, could or should occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernovas management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

More information:

Keywords (optional):

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: irw
print pressrelease  send to a friend  

Date: 07/05/2018 - 12:25
Language: English
News-ID 1538133
Character count: 6351
Firma: Sernova Corp.
Ansprechpartner: Feedback to about Pressrelease-id:
Stadt: Wien


Number of hits: 307


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 51

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.